MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided […]
Category Archives: Pr Newswire
Pr Newswire
Sprout Health NAD+ Injections — Compounding Status, Pharmacy Sourcing, and What Consumers Should Verify Before Any Telehealth NAD+ Enrollment in 2026
27
Feb
Feb
Compounded NAD+ Telehealth Access, FDA Classification, Pharmacy Sourcing Standards, Prescription Requirements, and Consumer Verification Steps for Evaluating Any NAD+ Injection Program in 2026 Encinitas, CA, Feb. 26, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Anti-aging, cellular health, and longevity concerns should be evaluated by a […]
27
Feb
Feb
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics’ President and CEO, Eric […]
27
Feb
Feb
MARKHAM, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 Highlights Adjusted EBITDA(1), excluding out-of-period items, increased by $12.2 million or 36.4% from Q4 2024 to $45.6 million, driven primarily by continued organic […]
HOLLYWOOD, Calif., Feb. 27, 2026 /PRNewswire/ — Netflix, Inc. today announced that it has declined to raise its offer for Warner Bros. Netflix had earlier received notice from Warner Bros. Discovery (WBD) that its Board of Directors has determined Paramount Skydance’s (PSKY) latest proposal constitutes a “Superior Proposal” under the terms of WBD’s existing merger […]
BRISBANE, Australia, Feb. 27, 2026 /PRNewswire/ — Jacobi Strategies (Jacobi), a global leader in investment technology, today announced the launch of its AI-Assisted Coding Resources, a powerful new suite of tools designed to help investment teams rapidly build, standardise, and scale bespoke analytics and applications within their secure, private Jacobi environment. Jacobi’s new AI resources […]
OXFORD, England, Feb. 27, 2026 /PRNewswire/ — Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration (TGA) class IIb approval in Australia for the Virtual Nodule Clinic (VNC) platform to support early lung cancer diagnosis. This important regulatory milestone was achieved after a […]
As the 2026 Best Workplaces for Women Australia List set to drop, Great Place To Work’s GM has thoughts on International Women’s Day, performative targets and being a voice for the next generation. SYDNEY, Feb. 27, 2026 /PRNewswire/ — Rebecca Moulynox has a low tolerance for cupcakes. Not the bakery treats themselves, she’s not a monster, […]
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States Follows a successful […]
Pr Newswire
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
26
Feb
Feb
Presentation showcases how Amphista’s Eclipsys® platform is enabling the development of Targeted Glue™ degraders, which recruit diverse E3 ligases, describing for the first time the degradation of KRAS G12D by the functional recruitment of DCAF11 Amphista’s proprietary target-centric approach enables the development of Targeted Glues™ with exceptional profiles with its first clinical candidate, AMX-883, a […]